(SAN) Sanofi - PA
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: PA (France) | Market Cap: 88.282m EUR | Total Return: 69.3% in 12m
Avg Turnover: 211M
EPS Trend: -65.1%
Qual. Beats: 0
Rev. Trend: 42.4%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, founded in 1994 (formerly Sanofi-Aventis until 2011). It operates across the full pharmaceutical value chain-from research and development through manufacturing and commercialization-spanning immunology and inflammation, rare diseases (including neurology), oncology, and a broad vaccines portfolio covering pediatric indications (polio, pertussis, Hib) as well as RSV, hepatitis A, typhoid, yellow fever, and rabies. The company pursues an externally-sourced innovation strategy, maintaining numerous collaboration and licensing agreements with biotech partners such as Exscientia, ABL Bio, Innate Pharma, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, and Scribe Therapeutics, among others. The pharmaceutical sector is characterized by high R&D intensity, heavy reliance on intellectual property protection, and increasing use of partnerships and AI-driven discovery platforms to supplement in-house pipelines and offset patent expirations.
- Dupixent franchise sales accelerate across atopic dermatitis and asthma indications
- Vaccines segment revenue normalizes as pediatric demand softens post-pandemic
- R&D pipeline partnerships expand oncology and immunology development pipeline
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.87 > 1.0 |
| NWC/Revenue: 0.34% < 20% (prev 26.24%; Δ -25.91% < -1%) |
| CFO/TA 0.16 > 3% & CFO 19.9b > Net Income 10.4b |
| Net Debt (16.3b) to EBITDA (14.8b): 1.10 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.20b) vs 12m ago -2.41% < -2% |
| Gross Margin: 64.03% > 18% (prev 70.93%; Δ -6.90% > 0.5%) |
| Asset Turnover: 35.74% > 50% (prev 34.08%; Δ 1.66% > 0%) |
| Interest Coverage Ratio: 12.76 > 6 (EBIT TTM 9.11b / Interest Expense TTM 714.0m) |
| A: 0.00 (Total Current Assets 30.2b - Total Current Liabilities 30.0b) / Total Assets 128b |
| B: 0.52 (Retained Earnings 66.9b / Total Assets 128b) |
| C: 0.07 (EBIT TTM 9.11b / Avg Total Assets 130b) |
| D: 1.33 (Book Value of Equity 72.8b / Total Liabilities 54.9b) |
| Altman-Z'' = 3.58 = A |
| DSRI: 1.04 (Receivables 482.0m/447.0m, Revenue 46.5b/45.0b) |
| GMI: 1.11 (GM 70.93% / 64.03%) |
| AQI: 1.16 (AQ_t 0.67 / AQ_t-1 0.58) |
| SGI: 1.03 (Revenue 46.5b / 45.0b) |
| TATA: -0.07 (NI 10.4b - CFO 19.9b) / TA 128b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of June 27, 2026, the stock is trading at EUR 75.07 with a total of 2,441,240 shares traded. Over the past week, the price has changed by -0.81%, over one month by +7.21%, over three months by +25.86% and over the past year by +69.34%.
Current recommended Stop Loss: 70.50 (which is 6.1% or 2.5 ATR below the current price).
Sanofi has no consensus analysts rating.
P/E Trailing = 18.6263
P/E Forward = 8.5034
P/S = 1.8643
P/B = 1.2091
P/EG = 3.6969
Revenue TTM = 46.5b EUR
EBIT TTM = 9.11b EUR
EBITDA TTM = 14.8b EUR
Long Term Debt = 12.3b EUR (from longTermDebt, last quarter)
Short Term Debt = 6.18b EUR (from shortTermDebt, last quarter)
Debt = 21.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.80b
Net Debt = 16.3b EUR (calculated: Debt 21.8b - CCE 5.54b)
Enterprise Value = 105b EUR (88.3b + Debt 21.8b - CCE 5.54b)
Interest Coverage Ratio = 12.76 (Ebit TTM 9.11b / Interest Expense TTM 714.0m)
EV/FCF = 6.60x (Enterprise Value 105b / FCF TTM 15.8b)
FCF Yield = 15.15% (FCF TTM 15.8b / Enterprise Value 105b)
FCF Margin = 34.10% (FCF TTM 15.8b / Revenue TTM 46.5b)
Net Margin = 22.30% (Net Income TTM 10.4b / Revenue TTM 46.5b)
Gross Margin = 64.03% ((Revenue TTM 46.5b - Cost of Revenue TTM 16.7b) / Revenue TTM)
Gross Margin QoQ = 72.09% (prev 36.58%)
Tobins Q-Ratio = 0.82 (Enterprise Value 105b / Total Assets 128b)
Interest Expense / Debt = 3.27% (Interest Expense 714.0m / Debt 21.8b)
Taxrate = 17.79% (1.66b / 9.34b)
NOPAT = 7.49b (EBIT 9.11b * (1 - 17.79%))
Current Ratio = 1.01 (Total Current Assets 30.2b / Total Current Liabilities 30.0b)
Debt / Equity = 0.30 (Debt 21.8b / totalStockholderEquity, last quarter 72.8b)
Debt / EBITDA = 1.10 (Net Debt 16.3b / EBITDA 14.8b)
Debt / FCF = 1.03 (Net Debt 16.3b / FCF TTM 15.8b)
Total Stockholder Equity = 71.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.97% (Net Income 10.4b / Total Assets 128b)
RoE = 14.41% (Net Income TTM 10.4b / Total Stockholder Equity 71.9b)
RoCE = 10.83% (EBIT 9.11b / Capital Employed (Equity 71.9b + L.T.Debt 12.3b))
RoIC = 7.35% (NOPAT 7.49b / Invested Capital 102b)
WACC = 5.68% (E(88.3b)/V(110b) * Re(6.42%) + D(21.8b)/V(110b) * Rd(3.27%) * (1-Tc(0.18)))
Discount Rate = 6.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -65.93 | Cagr: -1.77%
[DCF] Terminal Value 76.00% ; FCFF base≈15.6b ; Y1≈16.2b ; Y5≈18.4b
[DCF] Fair Price = 224.3 (EV 285b - Net Debt 16.3b = Equity 269b / Shares 1.20b; r=8.35% [WACC [floored]]; 5y FCF grow 4.40% → 2.50% )
EPS Correlation: -65.15 | EPS CAGR: -2.47% | SUE: 0.59 | # QB: 0
Revenue Correlation: 42.40 | Revenue CAGR: 2.94% | SUE: 1.19 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.86 | Chg30d=+0.00% | Revisions=+14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=3.02 | Chg30d=+0.00% | Revisions=-14% | Analysts=6
EPS current Year (2026-12-31): EPS=8.52 | Chg30d=+0.01% | Revisions=-14% | GrowthEPS=+8.8% | GrowthRev=+7.9%
EPS next Year (2027-12-31): EPS=9.01 | Chg30d=+0.11% | Revisions=-33% | GrowthEPS=+5.9% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -33%